ArticleBMC microbiology2025
In vitro activity of Eravacycline against carbapenem-resistant gram-negative bacilli and associated risk factors for non-susceptible infections from a tertiary hospital in fujian, China from 2021 to 2024.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Evolving Clonal, Plasmid-Mediated Resistome, Virulome and Therapeutic Landscape of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Assessment of Eravacycline Antimicrobial Susceptibility in China During the First Year Following Regulatory Approval (2023-2024): A Real-World Study.Microorganisms · 2025Article
- Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-ProducingAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study evaluated Eravacycline (ERV)'s effectiveness against carbapenem-resistant gram-negative bacteria (CRGNB) and identified risk factors for ERV non-susceptible Klebsiella pneumoniae (ENSKP) infections to support clinical treatment and early detection.
methodsBetween 2021 and 2024, 235 Carbapenem-Resistant Acinetobacter baumannii(CRAB) strains, 48 Carbapenem-Resistant Escherichia coli (CRECO) strains, and 158 Klebsiella pneumoniae (KP) strains were collected. Resistance genes were identified using PCR, and the minimum inhibitory concentration of tigecycline and ERV was determined using the broth microdilution method. Susceptibility was assessed according to U.S. Food and Drug Administration (FDA) and EUCAST breakpoints, and logistic regression identified ENSKP infection risk factors.
resultsFor CRAB, ERV's MIC50 and MIC90 were 0.5 µg/ml and 1 µg/ml, while tigecycline's were 2 µg/ml and 4 µg/ml. For Carbapenem-Resistant Klebsiella pneumoniae (CRKP), ERV's MIC50 and MIC90 were 0.5 µg/ml and 2 µg/ml, and tigecycline's were 2 µg/ml and 4 µg/ml. For CRECO, both ERV and tigecycline had MIC50 and MIC90 of 0.25 µg/ml and 0.5 µg/ml. The study found 25 KP strains non-susceptible to ERV, with no prior ERV treatment. The ENSKP group had higher ECOG scores, more invasive procedures, more antibacterial drug use, and longer hospital stays compared to the ERV susceptible KP.
conclusionOur study demonstrated that ERV effectively combats CRGNB, providing a potential basis for future treatment of drug-resistant infections. ENSKP infection can occur without ERV use. Effective surveillance and antibiotic stewardship are essential for managing ENSKP in high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.